Immunogenicity of Hepavax-Gene recombinant hepatitis B vaccine in INML workers, Colombia
Objective: To evaluate the immunogenicity of Hepavax-Gene recombinant hepatitis B vaccine in INML workers since the last administered doses. Methods: Cross-sectional study on 603 health workers with at least three administered recombinant vaccine doses. Antibody levels (anti-HBs) were measured using...
- Autores:
- Tipo de recurso:
- Fecha de publicación:
- 2007
- Institución:
- Universidad del Rosario
- Repositorio:
- Repositorio EdocUR - U. Rosario
- Idioma:
- eng
- OAI Identifier:
- oai:repository.urosario.edu.co:10336/23720
- Acceso en línea:
- https://repository.urosario.edu.co/handle/10336/23720
- Palabra clave:
- Hepatitis B antibody
Hepavax
Recombinant hepatitis B vaccine
Unclassified drug
Adult
Age distribution
Article
Cigarette smoking
Colombia
Dose time effect relation
Drug dose comparison
Drug efficacy
Enzyme linked immunosorbent assay
Female
Health care personnel
Hepatitis B
Human
Immunogenicity
Major clinical study
Male
Multivariate analysis
Occupational health
Prevalence
Sex difference
Hepatitis B
Immunogenicity
Vaccination
- Rights
- License
- Abierto (Texto Completo)
id |
EDOCUR2_aed031862ee0e3cae567dd42dcef55b7 |
---|---|
oai_identifier_str |
oai:repository.urosario.edu.co:10336/23720 |
network_acronym_str |
EDOCUR2 |
network_name_str |
Repositorio EdocUR - U. Rosario |
repository_id_str |
|
spelling |
55ba803e-3d54-45e9-92b3-bfb362dc0294-1794573976002020-05-26T00:04:48Z2020-05-26T00:04:48Z2007Objective: To evaluate the immunogenicity of Hepavax-Gene recombinant hepatitis B vaccine in INML workers since the last administered doses. Methods: Cross-sectional study on 603 health workers with at least three administered recombinant vaccine doses. Antibody levels (anti-HBs) were measured using the ELISA technique during December 2000 and January 2001, taking into account that the last dose in the vaccination varied between 1 and 6 years. Results: A total of 344 men and 259 women with an age mean of 38.8±7.3 years were studied. Protection levels were found in 90.7% (?10 U/1), decreasing significantly with the worker's age (p less than 0.00 1) and with the vaccine last dose administration time (p less than 0.01). Health workers with four doses compared to those with three doses had a 4.7% higher protection (antibody median 209.8 vs. 130.07, p less than 0.001). No association was found with gender (p=0.463), smoking (p=0.331) and blood exposure (p=0.433). Multivariate analyses found that no protection associated only with age (40-44 years HR=2.37, Cl 95%:1.18,4.78 and ?45 years HR=3.58, Cl 95%: 1.83,6.99). Conclusions: Although Hepavax-Gene recombinant hepatitis B vaccine (anti-HBs) has a high effectiveness in the health workers (90.7%) it presents a decrease in protection levels related to a higher worker's age and along vaccine last dose administration time. © 2007 Corporación Editora Médica del Valle.application/pdf1657953401208322https://repository.urosario.edu.co/handle/10336/23720engUniversidad del Valle-Facultad de Salud381No. 4375Colombia MedicaVol. 38Colombia Medica, ISSN:16579534, 01208322, Vol.38, No.4 (2007); pp. 375-381https://www.scopus.com/inward/record.uri?eid=2-s2.0-38349068912&partnerID=40&md5=4aa33def3e6d4a2d6537b38eb73ce849Abierto (Texto Completo)http://purl.org/coar/access_right/c_abf2instname:Universidad del Rosarioreponame:Repositorio Institucional EdocURHepatitis B antibodyHepavaxRecombinant hepatitis B vaccineUnclassified drugAdultAge distributionArticleCigarette smokingColombiaDose time effect relationDrug dose comparisonDrug efficacyEnzyme linked immunosorbent assayFemaleHealth care personnelHepatitis BHumanImmunogenicityMajor clinical studyMaleMultivariate analysisOccupational healthPrevalenceSex differenceHepatitis BImmunogenicityVaccinationImmunogenicity of Hepavax-Gene recombinant hepatitis B vaccine in INML workers, ColombiaImmunogenicidad de una vacuna recombinante anti-HBs en trabajadores de la salud, del instituto de Medicina Legal de ColombiaarticleArtículohttp://purl.org/coar/version/c_970fb48d4fbd8a85http://purl.org/coar/resource_type/c_6501Siachoque H.Ibáñez Pinilla, MilcíadesORIGINAL522-Manuscript-1578-1-10-20091125.pdfapplication/pdf258390https://repository.urosario.edu.co/bitstreams/e9dd0da1-2a6b-41fb-8f1e-48c4e814063c/download8483f541b3ef6465de9575b29d9bbf53MD51TEXT522-Manuscript-1578-1-10-20091125.pdf.txt522-Manuscript-1578-1-10-20091125.pdf.txtExtracted texttext/plain26965https://repository.urosario.edu.co/bitstreams/c26780be-a94f-477b-a2d0-1f70be0b161f/download130fae094b2cc836cb3a00d4ac3da413MD52THUMBNAIL522-Manuscript-1578-1-10-20091125.pdf.jpg522-Manuscript-1578-1-10-20091125.pdf.jpgGenerated Thumbnailimage/jpeg4287https://repository.urosario.edu.co/bitstreams/d7fbcfb2-0ae5-4df9-b612-0739c8fe1902/download471e6cfd57a444f498e8d4b1b647005dMD5310336/23720oai:repository.urosario.edu.co:10336/237202022-05-02 07:37:21.208365https://repository.urosario.edu.coRepositorio institucional EdocURedocur@urosario.edu.co |
dc.title.spa.fl_str_mv |
Immunogenicity of Hepavax-Gene recombinant hepatitis B vaccine in INML workers, Colombia |
dc.title.TranslatedTitle.spa.fl_str_mv |
Immunogenicidad de una vacuna recombinante anti-HBs en trabajadores de la salud, del instituto de Medicina Legal de Colombia |
title |
Immunogenicity of Hepavax-Gene recombinant hepatitis B vaccine in INML workers, Colombia |
spellingShingle |
Immunogenicity of Hepavax-Gene recombinant hepatitis B vaccine in INML workers, Colombia Hepatitis B antibody Hepavax Recombinant hepatitis B vaccine Unclassified drug Adult Age distribution Article Cigarette smoking Colombia Dose time effect relation Drug dose comparison Drug efficacy Enzyme linked immunosorbent assay Female Health care personnel Hepatitis B Human Immunogenicity Major clinical study Male Multivariate analysis Occupational health Prevalence Sex difference Hepatitis B Immunogenicity Vaccination |
title_short |
Immunogenicity of Hepavax-Gene recombinant hepatitis B vaccine in INML workers, Colombia |
title_full |
Immunogenicity of Hepavax-Gene recombinant hepatitis B vaccine in INML workers, Colombia |
title_fullStr |
Immunogenicity of Hepavax-Gene recombinant hepatitis B vaccine in INML workers, Colombia |
title_full_unstemmed |
Immunogenicity of Hepavax-Gene recombinant hepatitis B vaccine in INML workers, Colombia |
title_sort |
Immunogenicity of Hepavax-Gene recombinant hepatitis B vaccine in INML workers, Colombia |
dc.subject.keyword.spa.fl_str_mv |
Hepatitis B antibody Hepavax Recombinant hepatitis B vaccine Unclassified drug Adult Age distribution Article Cigarette smoking Colombia Dose time effect relation Drug dose comparison Drug efficacy Enzyme linked immunosorbent assay Female Health care personnel Hepatitis B Human Immunogenicity Major clinical study Male Multivariate analysis Occupational health Prevalence Sex difference Hepatitis B Immunogenicity Vaccination |
topic |
Hepatitis B antibody Hepavax Recombinant hepatitis B vaccine Unclassified drug Adult Age distribution Article Cigarette smoking Colombia Dose time effect relation Drug dose comparison Drug efficacy Enzyme linked immunosorbent assay Female Health care personnel Hepatitis B Human Immunogenicity Major clinical study Male Multivariate analysis Occupational health Prevalence Sex difference Hepatitis B Immunogenicity Vaccination |
description |
Objective: To evaluate the immunogenicity of Hepavax-Gene recombinant hepatitis B vaccine in INML workers since the last administered doses. Methods: Cross-sectional study on 603 health workers with at least three administered recombinant vaccine doses. Antibody levels (anti-HBs) were measured using the ELISA technique during December 2000 and January 2001, taking into account that the last dose in the vaccination varied between 1 and 6 years. Results: A total of 344 men and 259 women with an age mean of 38.8±7.3 years were studied. Protection levels were found in 90.7% (?10 U/1), decreasing significantly with the worker's age (p less than 0.00 1) and with the vaccine last dose administration time (p less than 0.01). Health workers with four doses compared to those with three doses had a 4.7% higher protection (antibody median 209.8 vs. 130.07, p less than 0.001). No association was found with gender (p=0.463), smoking (p=0.331) and blood exposure (p=0.433). Multivariate analyses found that no protection associated only with age (40-44 years HR=2.37, Cl 95%:1.18,4.78 and ?45 years HR=3.58, Cl 95%: 1.83,6.99). Conclusions: Although Hepavax-Gene recombinant hepatitis B vaccine (anti-HBs) has a high effectiveness in the health workers (90.7%) it presents a decrease in protection levels related to a higher worker's age and along vaccine last dose administration time. © 2007 Corporación Editora Médica del Valle. |
publishDate |
2007 |
dc.date.created.spa.fl_str_mv |
2007 |
dc.date.accessioned.none.fl_str_mv |
2020-05-26T00:04:48Z |
dc.date.available.none.fl_str_mv |
2020-05-26T00:04:48Z |
dc.type.eng.fl_str_mv |
article |
dc.type.coarversion.fl_str_mv |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
dc.type.coar.fl_str_mv |
http://purl.org/coar/resource_type/c_6501 |
dc.type.spa.spa.fl_str_mv |
Artículo |
dc.identifier.issn.none.fl_str_mv |
16579534 01208322 |
dc.identifier.uri.none.fl_str_mv |
https://repository.urosario.edu.co/handle/10336/23720 |
identifier_str_mv |
16579534 01208322 |
url |
https://repository.urosario.edu.co/handle/10336/23720 |
dc.language.iso.spa.fl_str_mv |
eng |
language |
eng |
dc.relation.citationEndPage.none.fl_str_mv |
381 |
dc.relation.citationIssue.none.fl_str_mv |
No. 4 |
dc.relation.citationStartPage.none.fl_str_mv |
375 |
dc.relation.citationTitle.none.fl_str_mv |
Colombia Medica |
dc.relation.citationVolume.none.fl_str_mv |
Vol. 38 |
dc.relation.ispartof.spa.fl_str_mv |
Colombia Medica, ISSN:16579534, 01208322, Vol.38, No.4 (2007); pp. 375-381 |
dc.relation.uri.spa.fl_str_mv |
https://www.scopus.com/inward/record.uri?eid=2-s2.0-38349068912&partnerID=40&md5=4aa33def3e6d4a2d6537b38eb73ce849 |
dc.rights.coar.fl_str_mv |
http://purl.org/coar/access_right/c_abf2 |
dc.rights.acceso.spa.fl_str_mv |
Abierto (Texto Completo) |
rights_invalid_str_mv |
Abierto (Texto Completo) http://purl.org/coar/access_right/c_abf2 |
dc.format.mimetype.none.fl_str_mv |
application/pdf |
dc.publisher.spa.fl_str_mv |
Universidad del Valle-Facultad de Salud |
institution |
Universidad del Rosario |
dc.source.instname.spa.fl_str_mv |
instname:Universidad del Rosario |
dc.source.reponame.spa.fl_str_mv |
reponame:Repositorio Institucional EdocUR |
bitstream.url.fl_str_mv |
https://repository.urosario.edu.co/bitstreams/e9dd0da1-2a6b-41fb-8f1e-48c4e814063c/download https://repository.urosario.edu.co/bitstreams/c26780be-a94f-477b-a2d0-1f70be0b161f/download https://repository.urosario.edu.co/bitstreams/d7fbcfb2-0ae5-4df9-b612-0739c8fe1902/download |
bitstream.checksum.fl_str_mv |
8483f541b3ef6465de9575b29d9bbf53 130fae094b2cc836cb3a00d4ac3da413 471e6cfd57a444f498e8d4b1b647005d |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 |
repository.name.fl_str_mv |
Repositorio institucional EdocUR |
repository.mail.fl_str_mv |
edocur@urosario.edu.co |
_version_ |
1818106608193896448 |